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Canine mammary cancer cells direct
macrophages toward an intermediate
activation state between M1/M2
Breno C.B. Beirão1†, Teresa Raposo1,2†, Lisa Y. Pang1 and David J. Argyle1*
Abstract
Background: Canine mammary carcinoma is the most common cancer in female dogs and is often fatal due to
the development of distance metastasis. The microenvironment of a tumour often contains abundant infiltrates of
macrophages called tumour-associated macrophages (TAMs). TAMs express an activated phenotype, termed M2,
which sustains proliferation of cancer cells, and has been correlated with poor clinical outcomes in human cancer
patients. Cancer cells themselves have been implicated in stimulating the conversion of macrophages to a TAM
with an M2 phenotype. This process has yet to be fully elucidated. Here we investigate the interplay between
cancer cells and macrophages in the context of canine mammary carcinoma.
Results: We show that cancer cells inhibit lipopolysaccharide (LPS)-induced macrophage activation. Further,
we show that macrophage associated proteins, colony-stimulating factor (CSF)-1 and C-C motif ligand (CCL)-2,
stimulate macrophages and are responsible for the effects of cancer cells on macrophages. We suggest the
existence of a feedback loop between macrophages and cancer cells; while cancer cells influence the phenotype of
the TAMs through CSF-1 and CCL2, the macrophages induce canine mammary cancer cells to upregulate their own
expression of the receptors for CSF-1 and CCL2 and increase the cancer cellular metabolic activity. However, these
cytokines in isolation induce a phenotypic state in macrophages that is between M1 and M2 phenotypes.
Conclusions: Overall, our results demonstrate the extent to which canine mammary carcinoma cells influence
the macrophage phenotype and the relevance of a feedback loop between these cells, involving CSF-1 and
CCL2 as important mediators.
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Background
Mammary tumours are the most common neoplasms that
affect female dogs (Canis familiaris), constituting half of all
tumours in female dogs. From these approximately half are
considered malignant [2, 3, 9]. In both women and dogs,
the incidence of mammary tumour increases with age,
rarely occurring before 25 and 5 years of age, respectively
[23] and is hormone dependent [19]. Canine mammary
carcinomas have epidemiologic, clinical, morphologic and
prognostic features similar to those of human breast cancer
and therefore represent a comparative model to understand
the underlying molecular mechanisms of carcinogenesis
and impacts of the tumour microenvironment in both
species [18, 19, 23].
Tumour-associated macrophages (TAMs) are major or-
chestrators of the tumour microenvironment by: sustain-
ing the proliferation of both cancer and stromal cells;
facilitating angiogenesis; suppressing the anti-tumoural
functions of T-lymphocytes; and enhancing the survival of
cancer stem cells [1–3, 9, 18, 19, 23]. It has subsequently
been shown that macrophage depletion improves outcome
in several cancer models [1, 17, 33] and validates TAMs as
potential therapeutic targets.
Macrophages are immune cells found in essentially all
tissues of the body, where they engulf apoptotic cells
and pathogens and produce immune effector molecules.
These cells are remarkably plastic and can change their
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functional phenotype depending on the environmental
cues they receive: macrophages can increase inflammation
and stimulate the immune system, and in contrast, also
play an important anti-inflammatory role and decrease
immune reactions through the release of cytokines.
Macrophages that are pro-inflammation are called M1
macrophages, whereas those that decrease inflammation
and encourage tissue repair are called M2 macrophages.
TAMs have an M2 phenotype and are predominately
activated by IL-4, IL-10 and CSF-1 secreted by the
tumour, whereas M1 macrophages are classically
activated by lipopolysaccharide (LPS) and IFNγ and
driven to phagocytosis [19]. Recent work has
highlighted the plasticity of macrophages and indi-
cates that transition forms of M1/M2 macrophages
coexist during tumour progression [27]. For example,
an intermediary form of macrophages has recently
been identified as regulatory macrophages, presenting
elevated IL-10 and low IL-12 secretion [4]. During
the M1-to-M2 transition of macrophages the molecu-
lar changes occurring can have profound effect on
breast cancer cell behaviour; notably, the levels of the
cytokines CSF-1 and CCL2 are elevated during this
transition [16, 32]. CSF-1 and CCL2 are known mod-
ulators of the fate of macrophages, both driving the
production of M2 cells and being correlated to poor
prognosis in cancer [5, 28].
Our understanding of the interaction between TAMs
and cancer cells is still evolving [6], as is the very classifica-
tion of M1/M2 macrophages [20]. Much is still debated
with regards to the origin, the variety of phenotypes, and
the actual roles of macrophages within tumours. While the
predominating view is that the tumour provides an envir-
onment that promotes an M2 phenotype, consensus is
shifting towards the idea that each individual macrophage
is a distinct unit that differs from its counterparts [20, 21].
For example, there is evidence that while capable of indu-
cing tumour invasion and expressing M2 markers, TAMs
also retain the ability to kill cancer cells when mediated by
anti-cancer antibodies [12].
In this study we aim to further understand the mutual
effects between cancer cells and macrophages by investi-
gating the role of CSF-1 and CCL2 stimulation on this
interaction and promotion of an M2 phenotype within the
context of canine mammary carcinoma. We found that
while CSF-1 and CCL2 drive the onset of M2 characteris-
tics, we propose that these cytokines also mediate activa-
tion of macrophages to a state that is not fully polarized.
Results
Macrophage activation can be inhibited by mammary
carcinoma cells
Macrophages are activated by LPS, a major component
of the outer membrane of gram-negative bacteria. Here,
LPS-induced macrophage activation was measured by
increased expression of MHC II and enhanced granu-
larity, as demonstrated by an increase in side scatter
(SSC) on flow cytometry. The enhanced side scatter may
indicate accumulation of enzyme-containing granules and
cellular activation [24]. To determine the interplay be-
tween cancer cells and macrophages, we co-cultured a
macrophage cell line (RAW) with either canine mammary
carcinoma cells (REM134), human mammary carcinoma
cells (MCF-7) or non-cancerous control cells (HEK293T).
The presence of either REM134 or MCF-7 cells sig-
nificantly reduced LPS-induced activation of RAW
macrophages as measured by both granularity
(Fig. 1a(i)) and expression of MHC II (Fig. 1a(ii) and
(iii)). The presence of non-cancerous HEK293T cells
had only a minor effect on macrophage activation
(Fig. 1a, b). Co-culture of macrophages and REM134
cells was also able to inhibit the expression of M2
macrophage marker CD301 in response to LPS-
induced activation, contrary to what would be ex-
pected; this cell surface marker was anticipated to be
increased with cancer cell-stimulation of the macro-
phages (Fig. 1b). These results demonstrate that both
canine and human mammary cancer cells can condi-
tion macrophages into a reduced activation state in
the presence of LPS, characteristic of M2 macro-
phages, but independent of the M2 marker CD301.
LPS-induced activation of macrophages is CCR2
dependent
The cytokine CCL2 is important for macrophage re-
cruitment and driving the M1 to M2 transition [29].
Here, we utilised the specific small molecule inhibitor
of the CCL2 receptor (CCR2). Macrophages were pre-
incubated with either the inhibitor alone or the in-
hibitor and exogenous CCL2 prior to treatment with
LPS. We found that inhibition of CCR2 had dual
effects: significantly inhibiting the activation of mac-
rophages as measured by the amount of high granu-
larity cells (Fig. 2a), and simultaneously increasing the
expression of MHC II before (Fig. 2b (i)) and after
(Fig. 2b (ii)) LPS-stimulation. The high granularity
cells were separated by FACS and were confirmed not
to be doublets (not shown). Interestingly, the basal
expression level of CD301 was induced by CCL2 but
compared to control cells was unaffected by the pres-
ence of the CCR2 inhibitor (Fig. 2c). Therefore, while
MHC II and CD301 expression levels indicate that CCL2
signalling leads to M2 characteristics, the cellular granu-
larity indicates that inhibiting CCR2 actually can decrease
this parameter of activation. Overall, these results indicate
that CCR2 signalling is important for the formation of
alternatively activated macrophages, but blocking CCR2
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also decreases the population of naturally highly granular
cells within the macrophage cell line.
Effects of mammary carcinoma cells on macrophages is
CSF1 dependent
Colony stimulating factor-1 (CSF-1) is associated with M2
activation of macrophages in cancer [29]. To investigate
the role of CSF-1 in the interaction between cancer cells
and macrophages, we utilised soluble recombinant canine
CSF-1 receptor (rcCSF-1R) to competitively inhibit free
CSF-1 [30] in co-culture experiments with RAW cells and
REM134 cells. The ability of the soluble recombinant re-
ceptor to bind CSF-1 was determined by ELISA (Fig. 3a).
The presence of canine mammary carcinoma cells de-
creased the LPS-induced activation of macrophages as
determined by granularity (Fig. 3b) and expression of
MHCII (Fig. 3c). This effect was rescued and enhanced by
inhibition of CSF-1, whereby LPS-induced activation of
macrophages – as determined by granularity (Fig. 3b) and
expression of MHCII (Fig. 3c) – was elevated 2.11-fold
and 1.53-fold respectively. This implies that cancer cell
mediated effects on macrophages are at least partially
dependent on CSF-1.
Effects of macrophages on mammary carcinoma cells
involves CSF1 and CCL2
We have shown that CCL2 is required for driving LPS-
induced activation of macrophages, and that CSF-1,
secreted from cancer cells, induces polarisation of
macrophages. We next assessed the effect of these cyto-
kines on canine cancer cells. Both macrophages (Fig. 4a
(i)) and REM134 (Fig. 4a (ii)) cells were incubated inde-
pendently with increasing concentrations of CSF-1, and
showed a dose-dependent increase in cell proliferation.
Interestingly, REM134 cells incubated with increasing
doses of CCL2 showed marginal effects on cell prolifera-
tion – 1.2-fold increase in proliferation at the highest
doses used – which was not dose-dependent at the stated
doses ((Fig. 4a (iii)). As an alternative method to assess
the effect of CCL2 on REM134 cells, we cultured
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Fig. 1 Cancer cells inhibit LPS induced activation of macrophages. Macrophages (RAW) were co-cultured with either canine mammary
carcinoma (REM), Human mammary cancer cells (MCF7) or non-cancerous cells (HEK293T), stimulated with 1 μg/ml LPS for 48 h.
LPS-induced activation of macrophages was measured by changes in granularity (a (i)), percentage of MHC II+ cells (a (ii)) or mean
fluorescence intensity of MHC II (a (iii)), and expression of the M2 marker, CD301 (b). Macrophages were distinguished from cancer cells
in flow cytometry by CSFE staining. All experiments are replicates of 4. Asterisks indicate statistically significant differences in relation to
LPS-treated cells, where P < 0.05 (unless where indicated) by Kruskal-Wallis test; “ns” indicates non-significant differences
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macrophages with increasing doses of CCL2 and then har-
vested the media, termed macrophage conditioned media.
This was subsequently used to treat REM134 cells, and
induced a CCL2 dose-dependent increase in cell prolifera-
tion (Fig. 4a (iv)). This data suggests that cancer cell pro-
liferation can be stimulated in a dose-dependent manner
directly by CSF-1 and indirectly via CCL2. Furthermore,
addition of macrophage conditioned media to mammary
cancer cells seemed to induce the expression of the recep-
tors required for the signalling of CSF-1 (CSF-1R) (Fig. 4b
(i)) and CCL2 (CCR2) (Fig. 4b (ii)).
We also analysed the cellular activity of REM134 cells
after treatment with macrophage-conditioned media by
assaying for glucose uptake. Here REM134 cells treated
with macrophage-conditioned media showed a higher
level of glucose uptake compared to untreated cells
(Fig. 4c). Glucose uptake of REM134 cells was also
measured at 4 °C as a negative control and with the
addition of ethanol as a vehicle control (VC). These
results indicate that cancer cells respond to factors
secreted by macrophages by upregulating: expression of
key signalling receptors; cellular proliferation; and cel-
lular activity.
Proliferation of canine mammary carcinoma cell lines is
dependent on CSF-1R
To determine the effect of inhibition of CSF-1 and
CCL2 signalling on cancer cells we utilised the small
Fig. 2 M1/M2 polarization of macrophages involves CCR2 signalling. RAW cells were pre-treated for 1 h with 10 μM RS102895 hydrochloride, a
small molecule inhibitor of CCR2 (CCR2i) prior to stimulation with 1 μg/ml LPS for 48 h. An equivalent volume of DMSO was used as a vehicle
control. LPS-induced activation of macrophages was measured by changes in the percentage of high granularity cells (a (i)) before (a (ii)) and
after LPS-treatment (a (iii)), expression of MHC II before (b (i)) or after LPS stimulation (b (ii)), and expression of the M2 marker, CD301 (c). All ex-
periments are replicates of 3. Asterisks indicate statistically significant differences in relation to the CCR2i treated cells, where P < 0.05 by Kruskal-
Wallis (Figure A) or ANOVA (Figures B and C); “ns” indicates non-significant differences
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molecule inhibitors of CSF-1R (GW2580) and CCR2
(RS102895). As a control we used the tyrosine kinase in-
hibitor, toceranib. Toceranib (Palladia®) inhibits phos-
phorylation of c-kit receptor tyrosine kinase and cell
proliferation of REM134 cells in a dose dependent
manner (unpublished data). Here we show that
REM134 cell proliferation is inhibited in a dose dependent
manner by inhibition of CCR2 (Fig. 5(i)), cKit (Fig. 5(ii)),
and CSF-1R (Fig. 5(iii)). To determine if these effects
are consistent in canine mammary carcinoma cell
lines, we utilised the inflammatory mammary carcin-
oma cell line, Lilly (a kind gift from Dr R. de Maria,
University of Turin, Italy). Lilly cells showed a dose-
dependent decrease in proliferation when treated with
GW2580 (Fig. 5(vi)), but not with the inhibitor of
CCR2 ((Fig. 5(iv)), or toceranib (Fig. 5(v)), highlight-
ing cell line dependent responses to treatment. How-
ever these results show that the proliferation potential of
both canine mammary carcinoma cell lines tested are
dependent on CSF-1R signalling.
Dual role of CSF-1 in stimulation of macrophages
CSF-1 is an important mediator of the interaction be-
tween macrophages and cancer cells. Here we investi-
gate the effect of recombinant CSF-1 on macrophages.
Macrophages were grown in media containing increas-
ing amounts of recombinant CSF-1 for 48 h and then
analysed for expression of the M1 marker, MHC II.
Basal MHC II expression levels increased in a dose
dependent manner in response to recombinant CSF-1
(Fig. 6a (i)). In contrast, exposing macrophages to
media containing increasing concentrations of CCL2
had no significant effect on basal MHC II levels (Fig. 6a
(ii)). To understand the effect of CSF-1 in driving pro
or anti-inflammatory properties, we studied two
markers of these characteristics by Western blot.
A
B
Granularity
RA
W
RA
W
+C
SF
1R
RA
W
+L
PS
RA
W
+L
PS
+C
SF
1
RA
W
+R
em
RA
W
+R
em
+L
PS
RA
W
+R
em
+L
PS
+C
SF
1
RA
W
+R
em
+L
PS
+C
SF
1R
0
50
100
150
200
*
ns * *
***
G
ra
n
u
la
ri
ty
 (
S
S
C
)
0 n
g
10
 n
g
20
 n
g
40
 n
g
0.0
0.5
1.0
1.5
2.0
CSF1R
BSA
CSF-1 concentration
A
b
so
rb
an
ce
 4
50
n
m
MHC II
RA
W
RA
W
+C
SF
1R
RA
W
+L
PS
RA
W
+L
PS
+C
SF
1
RA
W
+R
em
RA
W
+R
em
+L
PS
RA
W
+R
em
+L
PS
+C
SF
1
RA
W
+R
em
+L
PS
+C
SF
1R
0
5
10
15
20
*
* *
ns
*
* *
M
ea
n
 f
lu
o
re
sc
en
ce
C
Fig. 3 Cancer cell effects on macrophages are CSF-1 dependent. Canine recombinant CSF-1R binds to CSF-1 as detected by ELISA. BSA
was used as a control protein for coating the plate (a). REM134 cells, RAW cells and soluble canine recombinant CSF1R (1 μg/ml every
24 h) were co-cultured for 3 days prior to LPS-induced activation of macrophages. Activation of macrophages was measured by
granularity (b) and expression of MHC II (c). All experiments are replicates of 3. Asterisks indicate statistically significant differences in
relation to the LPS treated cells, where P < 0.05 by ANOVA; “ns” indicates non-significant differences
Beirão et al. BMC Veterinary Research  (2015) 11:151 Page 5 of 14
Exposure of macrophages to recombinant CSF-1 in-
creased the expression of the inflammation marker,
COX-2 and decreased expression of the anti-
inflammatory marker, Twist-1 (Fig. 6b), indicating that
CSF-1 conditioning of macrophages leads to an in-
flammatory phenotype.
LPS-induced activation of macrophages in the indi-
cated media showed that both CSF-1 (Fig. 6c (i)), and
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Fig. 4 CSF-1 and CCL2 contribute to cancer cell proliferation and activity. Macrophages (a (i)) and REM134 (a (ii)) cells were incubated
with increasing doses of CSF-1. Cellular proliferation was measured after 48 h. PBS + 0.1 % BSA was used a vehicle control at 0 ng/ml.
REM134 cells were incubated with increasing concentrations of CCL2 (a (iii)) or conditioned media (CM) from CCL2 treated macrophages
(a (iv)). Cellular proliferation was measured after 48 h. PBS + 0.1 % BSA was used a vehicle control at 0 ng/ml. Experiments are replicates
of 6. Statistical analysis considered each group against the control group. Expression of CSF-1R was assayed in Lilly cancer cells, after
exposure to macrophage conditioned media, by immunofluorescence (b (i)). Expression of CCR2 was measured in REM134 cells, after
exposure to macrophage-conditioned media, by qRT-PCR (b (ii)). Cellular activity was measured by glucose uptake. REM134 cells were
pre-incubated with macrophage-conditioned media for 72 h prior to analysis. Ethanol was used as a vehicle control (VC). Cells were
incubated at 4 °C as a negative control (c). Figures B and C are replicates of 3. Statistical analysis considered each group against the
REM group. Asterisks or horizontal bars indicate statistically significant differences to the 0 ng/ml or REM group, where P < 0.05 by
Kruskal-Wallis (Figure A) or Mann–Whitney (Figures B and C); “ns” indicates non-significant differences
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CCL2 (Fig. 6c (ii)) mediate a dose-dependent decrease
in MHC II levels in response to LPS activation, indi-
cating that CSF-1 plays a dual role in macrophage
activation.
Reduced expression of Twist-1 mimics the effect of CSF-1
stimulation
To determine if the effect of CSF-1 on macrophages
is mediated via the transcription factor Twist-1, we
reduced the levels of Twist-1 protein in macrophages
using siRNA to Twist-1 (Fig. 7a). This resulted in a
significant increase in basal MHC II levels compared
to mock transfected cells (Fig. 7b (i)). However LPS-
activation of macrophages showed no change in MHC
II levels and this was unaffected by Twist-1 expres-
sion levels. Granularity was again used as a measure
of macrophage activation. Reduction of Twist-1 levels
increased basal granularity marginally but with statis-
tical significance, and significantly decreased LPS-
induced activation of macrophages (Fig. 7b (ii)).As a
measure of cellular function we assayed the effect of
Twist-1 knock down on phagocytosis, and identified a
similar pattern to granularity. Reduction of Twist-1
levels slightly increased basal levels of phagocytosis com-
pared to control, but upon activation of macrophages by
LPS there was significantly decreased phagocytosis
(Fig. 7c). These results indicate that reduction in
Twist-1 levels mimics the effects of treating macro-
phages with recombinant CSF-1 and suggests that
CSF-1 acts upstream of Twist-1 to mediate macro-
phage polarisation.
Discussion
Distinct macrophage subsets have been linked with ei-
ther protective or pathogenic roles in cancer. A pro-
tective role has been described for M1 macrophages,
which activate tumour-killing mechanisms and antag-
onise the suppressive activity of TAMs. In contrast,
TAMs suppress adaptive tumour-specific immune re-
sponses and promote tumour growth, invasion, me-
tastasis, stroma remodelling and angiogenesis. TAMs
have a suppressive M2-like phenotype. Accumulating
evidence from many tumour models suggests that
macrophages contribute to tumour progression, with
increasing numbers of TAMs correlating with poor
outcomes. Here we investigated the interplay between
canine mammary carcinoma cells and macrophages.
We have shown that cancer cells and macrophages
have mutual effects on each other, and that the cyto-
kines CSF-1 and CCL2 are important mediators of
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Fig. 5 Proliferation of canine mammary carcinoma cells is CSF-1R dependent. Canine mammary carcinoma cell lines, REM134 and Lilly were
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Fig. 6 The dual role of CSF-1 in macrophage activation. Macrophages were incubated with media containing increasing concentrations of either
recombinant CSF-1 (a (i)) or recombinant CCL2 (a (ii)) for 2 days prior to analysis of MHC II expression by flow cytometry. Protein expression levels
of COX-2 and Twist were determined by Western blotting. β-actin was used as a loading control. 20 μg protein loaded (b). Macrophages were in-
cubated with media containing increasing concentrations of either recombinant CSF-1 (c (i)) or recombinant CCL2 (c (ii)) for 2 days prior LPS-
induced activation (300 μg/ml LPS for 48 h). MHC II expression levels were determined by flow cytometry. Figures (i) are replicates of 6, Figures
(ii) are replicates of 3. Asterisks indicate statistically significant differences to the RAW or RAW + LPS group, where P < 0.05 by
Kruskal-Wallis (Figures A(i) and C(ii)) or ANOVA, unless where indicated; “ns” indicates non-significant differences
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this interaction. Furthermore, we have identified that
CSF-1 is likely to signal via the transcription factor
Twist-1 to exert its effects on macrophage activation.
Our data corroborates previous studies. Wasserman et
al. (2012) demonstrated the capacity of several canine
cancer cells to inhibit macrophage MHC II expression,
therefore driving TAMs into the alternative M2-
activation pathway [32]. Król et al. (2012) [16] showed
that LPS-induced activation of macrophages was
inhibited by co-culturing macrophages with canine
mammary cancer cells. Here we utilised canine mam-
mary carcinoma cells and showed by cellular granularity
and MHC II expression of macrophages that REM134
cells can inhibit LPS-induced activation of macrophages.
There is currently controversy regarding the dogma of
classic and alternative macrophage activation, termed
M1 and M2, respectively. As research into macrophage
biology has evolved, so has the growing amount of
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Fig. 7 CSF-1 and Twist-1 are key mediators of macrophage activation. Twist-1 protein levels were depleted by treating with siRNA against
Twist-1 for 24 h. Immunofluorescence was carried out using anti-Twist-1 antibody (a). The effects of the reduction of Twist-1 levels on
LPS-induced activation of macrophages were assayed by expression of MHC II (b (i)); granularity (b (ii)); and phagocytosis (c). All experi-
ments are replicates of 3. Horizontal bars indicate statistically significant differences on a Student t-test, where P < 0.05, unless where indi-
cated; “ns” indicates non-significant differences
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information regarding recognition receptors, cytokines,
and the signalling and genetic programs behind them
that control an increasing number of functions of mac-
rophages. Therefore there is a need to recognise a
broader functional repertoire of macrophages that may
not fit into the distinct M1 and M2 classifications [20].
Furthermore, tumour microenvironments, compared to
a healthy tissue, are haphazard and may contain areas of
hypoxia, higher lactate, extracellular acidosis and glucose
starvation [8]. Within a tumour multiple and different
M1 and M2 stimuli may act on macrophages, and in this
context, macrophages may not form distinct activation
subsets nor clonally expand, leading to a spectrum of
macrophage phenotypes. As a marker of M2-activation
we used CD301. In contrast to the granularity and MHC
II expression data, expression of CD301 increased after
LPS-activation but was unaffected by the presence of
cancer cells, indicating that, in these culture conditions,
macrophages under the influence of cancer cells are in
an activation state between the extremes of the M1 or
M2 spectrum.
CSF-1 and CCL2 have well-characterised roles in
macrophage activation including inducing macrophage
survival and recruitment [17, 29]. Expression of both CSF-
1 and CCL2 have been independently correlated with can-
cer progression in several tumour types [28]. Our studies
show that blocking the receptor of CCL2, CCR2, with a
small molecule inhibitor could increase macrophage acti-
vation, and this supports previous studies where
RAW264.7 macrophages are able to produce this cytokine
[22] and, by blocking this autocrine signalling, induce cel-
lular activation. This may be mediated through Activin A,
which can simultaneously alter the expression of CCR2
and CCL2 in macrophages, depending on their previous
activation state [29]. Blocking CCR2 signalling is expected
to induce the expression of Activin A, which is known to
drive MHC II expression in macrophages, as well as
phagocytosis and other M1 characteristics [11]. We
showed that in the presence of LPS the effects of blocking
CCR2 were more pronounced. Here, blocking CCR2 in
macrophages allowed for a marked increase in cellular
activation. The addition of rhCCL2 could not reverse this
effect, demonstrating that blockade of the receptor was
complete. Interestingly, it has been shown that LPS treat-
ment alone can induce CCL2 expression in RAW264.7
macrophages as a negative feedback, since its expression
is controlled by STAT-3, an immune regulator [22, 31].
The effect of CCL2 on macrophages was confirmed by
CD301 expression. Adding recombinant CCL2 increased
expression of this marker. Overall, the results with CCL2
indicate a shift towards an M2 activation phenotype in
the presence of CCL2/CCR2 signalling. Another work
found that co-culture of macrophages and canine can-
cer cells reduced the relative expression of CCL2 by the
macrophages, but at the same time induced its expres-
sion by cancer cells [16], therefore supporting the
hypothesis that macrophages will be directed towards
an M2 phenotype in the presence of cancer cells. How-
ever, CCR2 blockade also had the opposite effect of re-
ducing the percentage of highly-granular macrophages.
These highly-granular cells represent only a small
fraction of the total macrophage population, but are
likely to represent an activated subset of the cellular
population [24]. Therefore, the reduction in the highly-
granular subgroup of macrophages in the absence of
CCR2 signalling points away from the more accepted
role of CCR2 inducing M2 polarization of TAMs.
As with CCL2, CSF-1 had a negative impact on LPS-
induced macrophage activation. While adding recombinant
CSF-1 reduced macrophage expression of MHC II following
LPS activation, blocking it with a soluble recombinant CSF-
1R allowed a marked activation of these cells. This indicates
that by blocking CSF-1R signalling, an inflammatory pheno-
type can be obtained, even in the presence of cancer cells.
Both macrophages and canine mammary cancer
cells are able to proliferate in the presence of rhCSF-
1. While CCL2 itself induces some cancer cell prolif-
eration, CCL2 conditioning of the macrophages in-
creases the effect that these cells have on cancer cell
proliferation. Macrophage conditioned media is also
capable of inducing expression of CSF-1R and CCR2
by mammary carcinoma cells, indicating that there is
a cycle whereby cancer cells induce macrophage pro-
liferation and phenotypic change, and the presence of
macrophages leads to cancer cell growth, with both
processes occurring, at least partially, through CSF-1R/
CCR2 signalling (Fig. 8). CSF-1R expressed by cancer
cells does not have any mutations compared to the na-
tive receptor (data not shown), indicating that it must
depend on either autocrine or paracrine signalling to
support cancer expansion. CSF-1R has been associated
with mammary cancer aggressiveness in dogs [14, 15],
and the expression of the receptor has been shown to
be increased in canine mammary adenocarcinoma cells
in co-cultures with macrophages [16].
The effect of macrophage conditioned media on the
cancer cells is biologically relevant since it increases
cancer cell metabolism, as measured by cellular glucose
uptake and cellular proliferation. Increased expression
of CCL2 can induce insulin resistance [13], which is
usually associated with hyperinsulinemia [25] and in-
creased glucose uptake by cancer cells. Lactic acid pro-
duction by tumour cells, generated as a consequence of
glucose metabolism, has been shown to be central for
the signalling that induces M2-macrophages (as mea-
sured by Arg-1 expression) and vascular endothelial
growth factor expression [6]. Therefore, when in con-
tact with macrophages, cancer cells will consume more
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glucose, thereby reinforcing an M2 phenotypic state on
the macrophages.
CSF-1R signalling is relevant both for macrophages
and cancer cells. However the role of CCL2 produced by
the cancer cells, as described previously [16], appears to
be confined to altering the macrophage phenotype, as
cancer cells themselves were unaffected by inhibition of
CCR2. The proliferative response of cancer cells to
CCL2-treated macrophage CM is probably due to activa-
tion of other receptors in the cancer cells by soluble
factors secreted from macrophages. This highlights the
complexity of the tumour microenvironment and the
importance of the secretome in the interplay between
cancer cells and TAMs.
Twist-1 is a transcription factor that has been associ-
ated with macrophage activation and function and in the
interaction between tyrosine kinase receptors (such as
CSF-1R) and Toll-like receptors (such as TLR4, the re-
ceptor for LPS) [7]. To assess the importance of Twist-1
signalling in the M1-to-M2 transition, expression of
Twist-1 was depleted in macrophages. A decrease in
Twist-1 protein levels lead to increased macrophage
activation, as measured by phagocytosis capacity, cell
granularity and MHC II expression. However, when LPS
was added, Twist-1 knock down only partially impeded
macrophage activation by LPS. Therefore, depletion of
Twist-1 had similar effects to treating macrophages with
recombinant CSF-1, indicating that CSF-1 may signal
through Twist-1 to mediate the M1-to-M2 transition.
Conclusions
In conclusion we have characterised the interplay be-
tween cancer cells and macrophages. We have shown
that there is a cycle mediated by the cytokines CSF-1
and CCL2, whereby cancer cells induce macrophage
proliferation and phenotypic changes, and macrophages
stimulate cancer cell proliferation. We have also
highlighted the importance of the transcription factor
Twist-1 in macrophage activation and that cancer-
related changes in glucose metabolism reinforce the M2
phenotypic state of macrophages. The tumour micro-
environment is highly complex and we have shown dual
roles for the cytokine, CSF-1 and CCL2 in the context of
macrophage activation, suggesting a spectrum of macro-
phage activation states. Future single-cell analysis of
tumours will provide further insight into the complexity
of macrophage activation, which will have ramifications for
both veterinary and human cancer treatment programs.
Methods
Cell culture
RAW264.7 mouse macrophages, REM134 canine mam-
mary cancer cell line [10], MCF7 human mammary can-
cer cell line, HEK293T human embryonic kidney and
Lilly canine inflammatory mammary cancer cell line
were used. All cell lines were grown in Dulbecco’s modi-
fied Eagle’s medium (DMEM) (Gibco) supplemented
with 10 % FBS, penicillin-streptomycin (100 μg/mL) and
glutamate (2 mM) (Gibco) in an atmosphere of 5 % CO2
and 95 % humidified air at 37 °C.
Co-cultures
For flow cytometry assays, macrophage and REM134
cells were grown in co-cultures or in the presence of
conditioned medium (CM) from RAW264.7 cells. For
co-cultures, RAW264.7 macrophages were stained with
COX-2
Twist-1
Phagocytosis
Cell granularity
M
Cancer cell
Cell proliferation
Glucose uptake
M2-phenotype
Fig. 8 Schematic representation of the molecular interactions following macrophage and cancer cell activation. Arrows indicate that the pathway
is increased; blunt-ended lines represent a negative effect on another receptor/pathway
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CFSE (eBioscience). Cells were grown at a ratio of 2:1 of
REM:RAW. Conditioned media was collected from sub-
confluent cultures grown for at least 48 h and added at
between 10–20 % of final culture volume. Co-cultures,
cell cultures with conditioned medium or cells that re-
ceived CSF1/CCL2/CCR2i were grown for at least 3 days,
when LPS (Sigma, L4391) would be added at 1 μg/ml
(when stated in the text) for at least 48 h. Cells were re-
moved from plate by trypsinization or scraping.
Drug treatment
RAW264.7 cells were treated with hrCSF-1 (Invitrogen)
[50 ng/ml], CCL2 [50 ng/ml] (R&D Systems), canine re-
combinant CSF-1R [1 μg/ml] every 24 h for 48 h, unless
indicated. Canine CSF-1R was expressed in HEK293T
cells from a pEF6-V5-His vector (Invitrogen) containing
the extracellular portion of the CSF-1R receptor. The re-
ceptor was affinity purified using Ni-NTA resin (Qiagen)
before adding to cell culture.
RAW264.7, REM134 and Lilly cells were treated with
CCR2 small molecule inhibitor (RS102895 hydrochloride
- Sigma) [10 μM] and CSF1R inhibitor (GW2580) 48 h
prior to analyses. DMSO was used as a vehicle control.
For the effect of CCL2 on LPS activation of RAW264.7
cells, cells were incubated with CCL2 for 5 days before
the addition of LPS.
Enzyme-Linked Immunosorbent Assay (ELISA)
Determination of binding of CSF-1 to canine recombinant
CSF-1R was performed by ELISA. Wells were coated with
500 ng of the extracellular portion of canine CSF-1R in
50 μl of PBS at 4 °C, overnight. Wells were blocked with
200 μl of PBS + 1 % BSA for 1 h at 37 °C. Human re-
combinant CSF-1 (Biolegend) was added at the stated
concentrations. Plate was washed 6 x with PBS + 0.05 %
Tween-20. Binding of CSF-1 was detected using anti-
CSF-1 (Peprotech) at 1:200. A HRP-conjugated second-
ary swine anti-rabbit antibody was added at 1:1700
(Dako). The reaction was developed using TMBUltra®
(Pierce). Colour development was stopped using 2 M
H2SO4 and the plate was read at 450 nm.
Cell viability
For cell proliferation assays, cells were grown in opaque
96-well plates. Conditions were tested on at least 4 rep-
licates. GW2580, toceranib phosphate or RS102895
hydrochloride were added at the stated concentrations.
Macrophage conditioned media was added to REM134
cells at 20 % of culture media volume. Cell proliferation
was analysed with CellTiter-Glo® (Promega) following
manufacturer’s instructions.
siRNA mediated gene silencing
For transient transfection of small interfering RNA
(siRNA) knockdown experiments, RAW264.7 cells were
transfected with siRNA using the Amaxa Cell Line
Nucleofector Kit V (Lonza,VCA-1003) according to the
manufacturer's instructions. Commercially available
TWIST1 and GAPDH siRNAs were purchased from
Thermo Scientific - Accel SiRNA technology. Gene
knockdown was validated by immunofluorescent stain-
ing of cells with an anti-Twist-1 antibody (see section
below). LPS treatment and phagocytosis assays were
carried out as described below.
Flow cytometry
For analysis of receptor expression, after removal from
culture plates, cells were incubated with the primary
antibody for 30 min at 0 °C. Primary antibodies: anti-
mouse MHCII I-A/I-E (eBioscience); anti-mouse CD301
(AbD Serotec). Phagocytosis analysis was performed
using 2 μm latex beads (Sigma). The beads were opson-
ized for 30 min at 37 °C with mouse serum IgG (Sigma)
before adding to the cells and incubating for 30 min at
37 °C. Glucose uptake was assessed using 2NBDG fluor-
escent glucose (Invitrogen) [50 μM] for 30 min at 37 °C
or 0 °C. Samples were analysed on a FACScalibur (BD).
Granularity was detected in the SSC channel, and fluor-
escence was detected using an argon laser. Sorting of
RAW264.7 cells for determination of cell doublets was
performed using a FACSAria II.
Western blotting
For Western blots, cell lysates were obtained of conflu-
ent culture (lysis buffer: 7 M urea; 0.1 M DTT; 0.05 %
Triton X-100; 25 mM NaCl; 20 mM Hepes-KOH,
pH7.6). Equal amounts of protein were separated by
SDS polyacrylamide gel electrophoresis (SDS-PAGE),
transferred to Hybond-C nitrocellulose membrane
(Amersham Pharmacia), and hybridised to an appropri-
ate primary antibody and HRP-conjugated secondary
antibody for subsequent detection by ECL. Primary
antibodies used were rabbit anti-Twist1 (Santa Cruz
Biotech); goat anti-COX-2 (Santa Cruz Biotech), mouse
anti-β-actin (Abcam). Secondary antibodies anti-mouse,
anti-goat and anti-rabbit were HRP-conjugated and
were used following manufacturer’s recommendations
(Dako).
Immunofluorescence
For immunefluorescent staining, cells were grown on
tissue culture treated chamber slides (Nunc Labtech)
overnight. Cells were fixed with ice cold acetone for
20 min and blocked with 10 % goat serum. Rabbit anti-
CSF1R (Abcam), rabbit anti-Twist1 (Sigma) were used.
Anti-mouse or anti-rabbit Alexa conjugated antibodies
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(Invitrogen) were used as secondary antibodies at 1:200
in 10 % goat serum/PBS. Slides were mounted with
aqueous mountant containing DAPI (Vectashield).
Quantitative real time PCR
Total cellular RNA was extracted using RNeasy® (Qia-
gen). RNA quality was determined by A260 measure-
ment. RT-PCR was performed with Omniscript (Qiagen)
using random nonamer primers (Sigma). Quantitative
RT-PCR (qPCR) was performed using Platinum SYBR
(Invitrogen). Assay was run on Mx3000P (Stratagene).
Primers are shown on Additional file 1.
Sequencing of CSF-1R from a canine cancer cell line
mRNA was extracted from the Lilly inflammatory canine
mammary carcinoma cell line using the RNeasy® kit
(Qiagen). cDNA was synthesized using random nonamers
(Sigma) and the Omniscript® (Qiagen) reverse-transcriptase
following the manufacturer’s instructions. The receptor was
amplified using the primers shown on Additional file 2 using
Phusion High-fidelity polymerase (Thermo). The product
was cloned into the pCR4-TOPO vector (Invitrogen) and
sequenced using the T3 and T7 primers, and also the
primers shown on Additional file 2. Sequencing performed
at DNA Sequencing and Services, Dundee, Scotland.
Statistical analysis
Normality tests were performed using the Minitab 16 soft-
ware. Kruskal-Wallis, Student t-test and ANOVA statistical
analyses (P < 0.05, unless indicated) were performed using
GraphPad Prism 5. qPCR data was normalized to the control
group and Log2 transformed before analysis. Unless indicated,
all graphs are shown as mean± standard deviation (SD).
Additional files
Additional file 1: Primers for quantitative real time PCR. Primers
shown from 5’ end to 3’ end.
Additional file 2: Primers for sequencing of CSF-1R from a cancer
cell line. Primers shown from 5’ end to 3’ end.
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